What is LOPJLB’s current signal on ARQT?

LOPJLB’s latest quantitative signal on Arcutis Biotherapeutics, Inc. (ARQT) is BUY in a RECOVERY regime. Signals are updated daily.

What market regime is ARQT in?

Arcutis Biotherapeutics, Inc. (ARQT) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Arcutis Biotherapeutics, Inc. (ARQT) do?

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's p…

Arcutis Biotherapeutics, Inc. (ARQT)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$26.09-0.50%Close

BUYRECOVERY · day 98

Company news

globenewswire.com · 5d ago

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

globenewswire.com · 8d ago

Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

defenseworld.net · 11d ago

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rated “Moderate Buy” by Wall Street Brokerages

globenewswire.com · 12d ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

defenseworld.net · 24d ago

Masaru Matsuda Sells 3,674 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

zacks.com · 27d ago

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

seekingalpha.com · 28d ago

Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

globenewswire.com · 40d ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com · 42d ago

Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

zacks.com · 47d ago

Here's Why You Should Add ARQT Stock to Your Portfolio Now

zacks.com · 48d ago

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

defenseworld.net · 48d ago

Bamco Inc. NY Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT

zacks.com · 49d ago

5 Biotech Stocks Worth Adding to Your Portfolio Now

defenseworld.net · 51d ago

382,682 Shares in Arcutis Biotherapeutics, Inc. $ARQT Bought by Deutsche Bank AG

globenewswire.com · 68d ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

fool.com · 69d ago

Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability

seekingalpha.com · 69d ago

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

zacks.com · 70d ago

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

marketbeat.com · 70d ago

Arcutis Biotherapeutics Q2 Earnings Call Highlights

globenewswire.com · 70d ago

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Market news & ticker search · RSS for ARQT

FAQ

What is LOPJLB’s current signal on ARQT?: LOPJLB’s latest quantitative signal on Arcutis Biotherapeutics, Inc. (ARQT) is BUY in a RECOVERY regime. Signals are updated daily.
What market regime is ARQT in?: Arcutis Biotherapeutics, Inc. (ARQT) is currently classified in the RECOVERY HMM market regime on LOPJLB.
What does Arcutis Biotherapeutics, Inc. (ARQT) do?: Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's p…

Arcutis Biotherapeutics, Inc. (ARQT)

Key stats

Industry peers

Prediction markets

Company news

FAQ